Tech transfer in biotech can feel like a high-stakes gamble, balancing regulatory shifts, incomplete data, and mounting stakeholder pressure—all with timelines breathing down your neck.

In this episode of the Smart Biotech Scientist Podcast, David Brühlmann shares hard-earned lessons on the complexities of tech transfer and scale-up in the biotech industry.

Key Topics Discussed

• A structured 6-pillar framework is essential for successful tech transfer in biotech.
• Deep technical understanding of processes, especially scaling effects, is critical to avoid failures.
• Strong analytical comparability ensures consistency and reduces risk during transfer.
• Quality by Design requires defining product quality and process parameters early, not later.
• Effective stakeholder communication and alignment are key to preventing conflicts.
• Choosing the right CDMO partner depends on capability, track record, and cultural fit.
• Strategic decisions between building in-house or outsourcing must consider long-term value and opportunity cost.

Episode Highlights

• The 6-pillar approach to turning tech transfer into a managed process, rather than a gamble [03:09]
• Why mass transfer physics and factors like kLA are critical—and how they can make or break a process at scale [05:12]
• The importance of analytical comparability, including the common blind spots in sampling plans and method validation [07:19]
• Establishing a solid Quality by Design (QbD) foundation and defining critical quality attributes before transfer, not after failures [08:33]
• Stakeholder management and why non-technical challenges often derail projects (with more on this in Part 2) [10:09]
• Evaluating CDMO partners: What selection criteria really matter for long-term success and risk mitigation [11:03]
• Strategic decision-making: Building core capabilities versus outsourcing, and how to avoid unnecessary costs and delays [12:22]

Turn Tech Transfer from a Gamble into a Managed Process: The 6-Pillar Biologics Scale-Up Framework

Introduction

Our process development head leaned back in his chair and smiled. "Guys, I have a quick tech transfer to our existing facility. Piece of cake."

Those were his exact words. And I believed him. Why wouldn't I? We had the process nailed. The timeline was tight but doable. The receiving site had done this before.

Except here's what nobody told me: regulatory requirements had evolved. Our process documentation was Swiss cheese. And what I thought was a robust process? It was a house of cards held together by undocumented operator tricks.

Maybe you're staring at a similar situation right now. Timeline pressure mounting. Stakeholders asking for updates you can't confidently give. That nagging feeling that there's something critical you're missing.

You're not wrong to feel that way.

Today, I'm giving you the framework that could've saved our team months of delays and millions in costs. The six-pillar approach that turns tech transfer from a gamble into a managed process.

The Problem and Framework

What You'll Learn Today

Here's what we're covering. First, the six essential pillars in every tech transfer—and why missing just one of them puts your project at risk. Second, the technical essentials, specifically why mass transfer physics change everything at scale. Third, the stakeholder strategy that turns resistance into genuine partnership. Fourth, when to build internal capability versus outsource—the decision framework nobody teaches you in grad school. And fifth, real implementation: your 12-week tech transfer preparation protocol.

Why This Matters

FDA data shows that over 40% of CMC-related IND issues trace back to manufacturing problems. Not formulation. Not analytics. Manufacturing. And here's the thing—tech transfer is now the number one CDMO differentiation factor. Lonza's data projects that by 2029, 56% of all biologics will be manufactured by CDMOs.

The hidden cost? Poor tech transfer doesn't just delay your program. It questions comparability. It my lead to expensive bridging studies. It hands your competitor the market window you were counting on.

But here's your opportunity. Master this, and you compress timelines while everyone else scrambles to put out fires. You become the person leadership trusts with the critical path.

So let's talk about the six pillars.

Pillar 1: Technical Process Understanding

Here's the physics challenge you need to tackle. What works brilliantly at 2 liters can fail spectacularly at 2,000 liters. Not because you did something wrong. Because physics changes.

Mass transfer is the big one. Specifically, kLa—oxygen transfer coefficient. Lars Puiman and Rik Volger explained this well on the podcast. Bubble size changes with scale. Residence time changes. Mixing patterns change.

Here's a concrete example. Your 2-liter benchtop bioreactor might have a kLa of 15 to 25 per hour. Your 2000-liter production vessel? You're looking at 8 to 15 per hour. That's roughly a 40 to 60% reduction in oxygen transfer efficiency—and if you're not planning for it, your high-density fed-batch is going to underperform at scale.

Now think about what that means for a high-density fed-batch culture. If your cells are oxygen-limited at production scale but not at bench scale, you're going to see different growth profiles. Different metabolite accumulation. Different product quality.

Your action item here is straightforward but not easy. Map every critical process parameter and ask: is this scale-dependent or scale-independent? Temperature setpoint? Scale-independent. Mixing time? Very scale-dependent. Impeller tip speed? Scale-dependent. pH control strategy? Depends on your system. Can your large-scale bioreactor system supply the oxygen your cell line needs?

Make that list before you commit to a tech transfer timeline.

Pillar 2: Analytical Comparability

Here's the blind spot I’ve seen. Teams obsess over the process—feed rates, temperature profiles, aeration strategy. And they completely neglect the sampling plan.

Let me be direct. Analytics isn't separate from tech transfer. It IS tech transfer.

Think about it. How do you prove your process transferred successfully? You measure it. And if your analytical methods aren't validated at the receiving site, or if your sampling plan doesn't have statistical power, you're building conclusions on quicksand.

What you need is side-by-side comparability with real rigor. Full product characterization panel for the final product. And forced degradation studies to demonstrate that your comparability holds up under stress.

This is where most tech transfers actually fail. Not because the process drifted. Because nobody designed a sampling strategy robust enough to detect when it drifted.

Pillar 3: Quality by Design Foundation

Gene Lee said something on the podcast that should be tattooed on every CMC scientist's forehead: "Start CMC planning early—you can't retrofit smart strategy."

Here's the Quality by Design chain: Quality Target Product Profile flows to Critical Quality Attributes, which flow to Critical Process Parameters. If you don't know what quality means for your pr oduct, you literally cannot transfer the process. Because you don't know what to measure and you don't know what to control.

The mistake I see repeatedly? Teams hoping the CDMO will figure it out. They ship over a process description and some batch records and say, "Make it work."

That's not a tech transfer. That's a wish.

Your CDMO will execute your plan. If you don't provide one, they'll improvise. And their improvisation might be scientifically sound and completely wrong for your regulatory strategy.

Define your CQAs before tech transfer. Not during the crisis call after the first batch fails.

Pillar 4: Stakeholder Management

I'm going to tell you about the QC guy who taught me the most important tech transfer lesson of my career. And it had absolutely nothing to do with science.

But that's coming in Part 2. Stay tuned for what derails many projects: stakeholder management.

Pillar 5: Partner Selection and Management

CDMO reality check. Your CDMO partner has deep expertise. They've scaled up hundreds of processes. But they execute YOUR plan.

If you don't have a plan, they will improvise. And that improvisation might be brilliant. It also might be completely misaligned with your regulatory strategy, your competitive timeline, or your quality requirements.

Selection criteria matter more than most people realize. According to Lonza, technology transfer capabilities have become a critical differentiator for successful partnerships and risk mitigation. Technical capability is table stakes. But you also need regulatory track record—have they filed INDs in your modality? And cultural fit—do they ask hard questions, or do they promise "no problem" to everything?

That second one is actually a red flag. The CDMO that promises smooth sailing without probing your process understanding? They're either overconfident or they don't care enough to push back.

You want the partner who challenges your assumptions early. Not the one who surfaces problems after you've committed three months and half a million dollars.

Pillar 6: Strategic Build vs. Outsource

Alfredo Martínez gave us the principle: Think holistically before building—infrastructure is expensive.

And not just expensive in capital. Expensive in time. Expensive in opportunity cost. Expensive in the expertise you need to hire and retain.

I'll give you the full decision framework in Part 2. But here's the preview question: Are you building core competitive advantage or are you building commodity infrastructure?

Because if it's commodity infrastructure, somebody else has already built it better and cheaper.

That's the framework. Six pillars that most people never think about systematically. But knowing the pillars isn't enough. You need the playbook.

Thank you for listening to Part 1. In Part 2, I'm walking you through real implementation: the QC conflict story that changed how I think about stakeholders, the light exposure discovery that taught me to document everything, your 12-week preparation protocol with go/no-go gates, and the build-versus-outsource decision matrix.

If you liked today’s conversation about scale-up and tech transfer, please tell us by leaving a review. Your review helps scientists like you discover these resources.

For additional bioprocessing tips, visit us at www.smartbiotechscientist.com. Stay tuned for more inspiring biotech insights in the next episode. Until then, let’s continue to smarten up biotech.

Disclaimer: This transcript was generated with the assistance of artificial intelligence. While efforts have been made to ensure accuracy, it may contain errors, omissions, or misinterpretations. The text has been lightly edited and optimized for readability and flow. Please do not rely on it as a verbatim record.

Next Step

Book a free consultation to help you get started on any questions you may have about bioprocess development: https://bruehlmann-consulting.com/call

Further Listening

If you’re interested in the ideas discussed, here are some of the guests David referenced in this episode.

Episodes 91 - 92: Mass Transfer Secrets: Mastering Bubbles and kLa from Bench to Large-Scale Production with Lars Puiman & Rik Volger

Episodes 79 - 80: Think Before You Build: Holistic Approaches to Biotech Facility Design with Alfredo Martínez Mogarra

Episodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias Müllner

Episodes 23 - 24: Strategies for Success: Master CMC Development with Gene Lee

He is also a biotech technology innovation coach, technology transfer leader, and host of the Smart Biotech Scientist podcast—the go-to podcast for biotech scientists who want to master biopharma CMC development and biomanufacturing.  

Hear It From The Horse’s Mouth

Want to listen to the full interview? Go to Smart Biotech Scientist Podcast. 

Want to hear more? Do visit the podcast page and check out other episodes. 
Do you wish to simplify your biologics drug development project? Contact Us